Sirukumab - Janssen Biotech

Drug Profile

Sirukumab - Janssen Biotech

Alternative Names: CNTO-136; PLIVENSIA™; Shirukumabu

Latest Information Update: 16 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Centocor
  • Developer Centocor; GlaxoSmithKline; Janssen Biotech
  • Class Antidepressants; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Giant cell arteritis
  • Phase II Asthma; Lupus nephritis; Major depressive disorder
  • Preclinical Atherosclerosis
  • Preregistration Submission Withdrawal Rheumatoid arthritis

Most Recent Events

  • 19 Oct 2018 Pooled adverse events data from the SIRROUND-D, SIRROUND-M, SIRROUND-T and SIRROUND-H phase III trials in Rheumatoid arthritis presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2018)
  • 24 Jun 2018 Biomarkers information updated
  • 22 May 2018 Janssen completes a phase-II clinical trials in Major depressive disorder (Adjuvant therapy) in United Kingdom, USA, Russia, Poland, Canada (SC) (NCT02473289)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top